GRAHAM JONES | PANMURE
Reckitt’s top line seems slightly weaker than expected. Pharma growth remains strong however, and the fact that Suboxone [heroin substitute] film strips have already grabbed 25 per cent of the market in the US is positive. It is a mixed picture with pharma muddying the waters.
MIKE HUGHES | DATAMONITOR
Reckitt Benckiser’s continued expansion in developing markets has helped offset rising commodity prices and a decline in revenue in its biggest market – Europe. With this in mind, in the short term, at least, Reckitt Benckiser should continue to keep its focus on emerging markets to ensure future growth.
KEITH BOWMAN | HARGREAVES LANSDOWN
Despite progressive results, Reckitt has fallen victim to high expectations and increased uncertainties going forward. Sales in the emerging markets continue to expand, while the group’s move to strengthen its healthcare product range remains ongoing – both underlined by an Indian healthcare company acquisition [Paras Pharmaceuticals] back in December 2010.